Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke
Launched by DONGTAN SACRED HEART HOSPITAL · May 14, 2013
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called repetitive transcranial magnetic stimulation (rTMS) to help improve movement in patients who have had a stroke and have weakness on one side of their body, known as hemiplegia. Stroke can leave survivors with long-lasting challenges, and traditional rehabilitation methods may not always be enough. rTMS is a safe, non-invasive technique that uses magnetic pulses to stimulate specific areas of the brain, potentially helping to restore some lost functions.
To be eligible for this trial, participants should be at least 18 years old, have experienced a stroke more than two weeks ago, and have some degree of weakness in their motor skills. However, individuals with a history of previous strokes, certain medical implants, or seizure disorders cannot participate. If you join the trial, you can expect to receive rTMS treatment while being monitored for any effects on your motor recovery. This study aims to find out if this new approach can help improve movement after a stroke, which could lead to better rehabilitation options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • stroke patients with motor weakness
- • Medical research council (MRC) grade 0-4
- • More than 2 weeks after stroke onset
- • Age 18 years and older
- • Able to provide consent for the protocol
- Exclusion Criteria:
- • History of previous symptomatic stroke
- • pregnant women
- • Persons with surgically or traumatically implanted foreign bodies such as a pacemaker, an implanted medication pump, a metal plate in the skull, or metal inside the skull or eyes (other than dental appliances or fillings), intracardiac lines that may pose a physical hazard during magnetic stimulation will also be excluded
- • Patients with history of seizure disorder or epilepsy
- • Subjects without the capacity to give informed consent
About Dongtan Sacred Heart Hospital
Dongtan Sacred Heart Hospital is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. Situated in Dongtan, South Korea, the hospital is equipped with state-of-the-art facilities and a team of highly skilled professionals committed to improving health outcomes. As a sponsor of clinical trials, Dongtan Sacred Heart Hospital emphasizes ethical practices, rigorous scientific methodologies, and collaboration with international research communities, aiming to contribute valuable insights to the fields of medicine and patient treatment. Their focus on patient safety and comprehensive data analysis ensures the integrity and reliability of their research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hwaseong Si, Gyeonggi Do, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials